NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:47:28 ON 22 DEC 2006

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 20:47:58 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 21 Dec 2006 (20061221/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 311773-65-6/rn
2 311773-65-6
0 311773-65-6D
L1 2 311773-65-6/RN
(311773-65-6 (NOTL) 311773-65-6D)

=> d rn

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
RN 56-65-5
RN 60-92-4
RN 7440-70-2
RN 127464-60-2
RN 107235-67-6
RN 171286-07-0
RN 311773-65-6
RN 329350-38-1

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.69	4.90

FILE 'REGISTRY' ENTERED AT 20:48:31 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0
DICTIONARY FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 329350-38-1/RN

L2 1 329350-38-1/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L2 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 329350-38-1 REGISTRY
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester
(9CI) (CA INDEX NAME)
MF C27 H33 N O5
SR Chemical Library
Supplier: AsInEx
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file caplus uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	7.24

FILE 'CAPLUS' ENTERED AT 20:49:04 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'USPATFULL' ENTERED AT 20:49:04 ON 22 DEC 2006

=> s 107235-67-6/rn or 171286-07-0/rn or 311773-65-6/rn or 329350-38-1/rn
L3 6 107235-67-6/RN OR 171286-07-0/RN OR 311773-65-6/RN OR 329350-38-1/RN

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 5 DUP REM L3 (1 DUPLICATE REMOVED)

=> d ibib abs hitstr 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:967920 CAPLUS
DOCUMENT NUMBER: 144:160688
TITLE: Ethyl 2-amino-4-(4-methoxyphenyl)-4H-benzo[h]chromene-3-carboxylate
AUTHOR(S): Guo, Cheng; Gu, Xi feng
CORPORATE SOURCE: Department of Applied Chemistry, College of Science, Nanjing University of Technology, Nanjing, 210009, Peop. Rep. China
SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2005), E61(9), o3101-o3103
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2005/09/00/ww6411/ww6411Isup2.hkl
PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB The title compound, C23H21NO4, was synthesized by the reaction of 1-naphthol with Et cyanoacetate and 4-methoxybenzaldehyde in EtOH under microwave irradiation Crystallog. data are given. In the structure of C23H21NO4, there are intramol. and intermol. N-H···O H bonds, also C-H···π interactions.
IT 171286-07-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)
RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:703127 CAPLUS
DOCUMENT NUMBER: 141:200235
TITLE: Methods of treating conditions associated with an Edg-3 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167185	A1	20040826	US 2004-760064		20040116
PRIORITY APPLN. INFO.:			US 2003-440325P	P	20030116

OTHER SOURCE(S): MARPAT 141:200235
AB The invention provides a method of inhibiting the Edg-3 receptor - mediated biol. activity in a cell. A cell expressing the Edg-3 receptor is contacted with an amount of an Edg-3 receptor inhibitor sufficient to inhibit the Edg-3 receptor - mediated biol. activity. Preferably, the inhibitor is not a phospholipid. Also the invention provides a method where an Edg-3 receptor - mediated biol. activity is inhibited in a subject. A therapeutically effective amount of an inhibitor of the Edg-3 receptor is administered to the subject. Preferably, the inhibitor is not a phospholipid.
IT 107235-67-6 171286-07-0 311773-65-6
329350-38-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating conditions associated with Edg-3 receptor)
RN 107235-67-6 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-

methylbutyl)- (9CI) (CA INDEX NAME)



RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 311773-65-6 CAPLUS
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 329350-38-1 CAPLUS
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:591307 CAPLUS
DOCUMENT NUMBER: 139:143997
TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): Ceretek LLC, USA
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	A1	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T	20050707	JP 2003-562260	20030121
US 2005261298	A1	20051124	US 2003-390428	20030314

PRIORITY APPLN. INFO.:

US 2002-350445P	P	20020118
US 2002-350446P	P	20020118
US 2002-350447P	P	20020118
US 2002-350448P	P	20020118
WO 2003-US1881	W	20030121
US 2003-352579	B2	20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT 107235-67-6 171286-07-0 311773-65-6 329350-38-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 107235-67-6 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)



RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 311773-65-6 CAPLUS
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 329350-38-1 CAPLUS
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:788057 CAPLUS
DOCUMENT NUMBER: 124:8590
TITLE: The synthesis of 2-amino-4-aryl-3-ethoxycarbonyl-4H-naphtho[1,2-b]pyrans revisited
AUTHOR(S): Martin, Nazario; Martinez-Grau, Angeles; Seoane, Carlos; Marco, Jose L.
CORPORATE SOURCE: Facultad Quimica, Universidad Complutense, Madrid,

28040, Spain
SOURCE: Journal of Heterocyclic Chemistry (1995), 32(4), 1225-8
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:8590

AB An expeditious and unequivocal synthesis of 2-Amino-4-phenyl-4H-naphtho[1,2-b]pyran-3-carboxylic acid Et esters was reported. Previous papers describing the preparation of this type of compound have been amended and a convenient and direct procedure for its preparation is now presented.

IT 171286-07-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (amino)arylnaphtho[1,2-b]pyrancarboxylates)

RN 171286-07-0 CAPLUS

CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:119824 CAPLUS
DOCUMENT NUMBER: 106:119824
TITLE: Synthesis and biological activity of 2-aryliminobarbituric acids
AUTHOR(S): Zaks, A. S.; Goncharenko, S. B.; Voronin, V. G.; Usachev, E. A.; Portnov, Yu. N.; Rabotnikov, Yu. M.; Pchelintseva, L. E.
CORPORATE SOURCE: VNIKhFI, Omnintsk, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1986), 20(5), 556-9
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 106:119824
GI



I, X=NR2
II, X=S

AB Inflammation-inhibiting aryliminobarbituric acids I (R = Et; R1 = Et, sec-pentyl; R2 = Ph, substituted Ph, PhCH2) were prepared in 56-83% yields by treating thiobarbituric acids II with R2NH2 6-12 h at 160-180°. I (R = R1 = Et, R2 = PhCH2) inhibited inflammation in rats 37% after 5 h

at 6 mg/kg dosage.

IT 107235-67-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)

RN 107235-67-6 CAPLUS

CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)



L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 311773-65-6 REGISTRY
ED Entered STN: 28 Dec 2000
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)
MF C26 H26 N2 O
SR Chemical Library
Supplier: Chemical Block Ltd.
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:788057 CAPLUS
DOCUMENT NUMBER: 124:8590
TITLE: The synthesis of 2-amino-4-aryl-3-ethoxycarbonyl-4H-naphtho[1,2-b]pyrans revisited
AUTHOR(S): Martin, Nazario; Martinez-Grau, Angeles; Seoane, Carlos; Marco, Jose L.
CORPORATE SOURCE: Facultad Quimica, Universidad Complutense, Madrid, 28040, Spain
SOURCE: Journal of Heterocyclic Chemistry (1995), 32(4), 1225-8
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:8590

AB An expeditious and unequivocal synthesis of 2-Amino-4-phenyl-4H-naphtho[1,2-b]pyran-3-carboxylic acid Et esters was reported. Previous papers describing the preparation of this type of compound have been amended and a convenient and direct procedure for its preparation is now presented.

IT 171286-07-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (amino)arylnaphtho[1,2-b]pyrancarboxylates)
RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.69	4.90

FILE 'REGISTRY' ENTERED AT 20:48:31 ON 22 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0
DICTIONARY FILE UPDATES: 21 DEC 2006 HIGHEST RN 916201-86-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 329350-38-1/RN

L2 1 329350-38-1/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L2 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 329350-38-1 REGISTRY
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester
(9CI) (CA INDEX NAME)
MF C27 H33 N O5
SR Chemical Library
Supplier: AsInEx
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

C:\Program Files\Stnexp\Queries\edg-3-1.str





chain nodes :
1 2 3 4 5 7
chain bonds :
1-2 1-3 1-7 3-4 3-5
exact/norm bonds :
1-3 1-7 3-4
exact bonds :
1-2 3-5

G1:X,A,Q,Cb,Cy,Hy,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS

C:\Program Files\Stnexp\Queries\edg-3-2.str





chain nodes :
27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 24 25 26
chain bonds :
4-12 10-22 25-27 27-28
ring bonds :
1-7 1-3 1-2 2-10 2-24 3-4 3-26 4-5 5-6 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22 24-25 25-26
exact/norm bonds :
1-7 2-10 3-4 4-5 5-6 6-7 7-8 8-9 9-10 25-27 27-28
exact bonds :
4-12 10-22
normalized bonds :
1-3 1-2 2-24 3-26 11-12 11-16 12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22 24-25 25-26

G1:X,A,Q,Cb,Cy,Hy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS

```
http://www.cas.org/infopolicy.html

=> s 311773-65-6/rn
             2 311773-65-6
             0 311773-65-6D
L1           2 311773-65-6/RN
                  (311773-65-6 (NOTL) 311773-65-6D )

=> d l1 rn

L1   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
RN   56-65-5
RN   60-92-4
RN   7440-70-2
RN   127464-60-2
RN   107235-67-6
RN   171286-07-0
RN   311773-65-6
RN   329350-38-1


=> select l1
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E8 ASSIGNED

=> d sel
E1           1     107235-67-6/BI
E2           1     127464-60-2/BI
E3           1     171286-07-0/BI
E4           1     311773-65-6/BI
E5           1     329350-38-1/BI
E6           1     56-65-5/BI
E7           1     60-92-4/BI
E8           1     7440-70-2/BI


=> s e1-e5
             3 107235-67-6/BI
         16459 127464-60-2/BI
             4 171286-07-0/BI
             2 311773-65-6/BI
             2 329350-38-1/BI
L2       16462 (107235-67-6/BI OR 127464-60-2/BI OR 171286-07-0/BI OR 311773-65
               -6/BI OR 329350-38-1/BI)

=> s l2 and (cancer or tumor or cancer? or neoplastic or neoplas? or sarcoma or
tumour)
        300932 CANCER
         44039 CANCERS
        312327 CANCER
                  (CANCER OR CANCERS)
        392964 TUMOR
        153361 TUMORS
        441579 TUMOR
                  (TUMOR OR TUMORS)
        316067 CANCER?
         57445 NEOPLASTIC
            15 NEOPLASTICS
         57455 NEOPLASTIC
                  (NEOPLASTIC OR NEOPLASTICS)
        474717 NEOPLAS?
         38205 SARCOMA
```

	4287	SARCOMAS
	100	SARCOMATA
	39862	SARCOMA
		(SARCOMA OR SARCOMAS OR SARCOMATA)
	3088	TUMOUR
	1161	TUMOURS
	4186	TUMOUR
		(TUMOUR OR TUMOURS)
L3	8081	L2 AND (CANCER OR TUMOR OR CANCER? OR NEOPLASTIC OR NEOPLAS? OR SARCOMA OR TUMOUR)

L26 ANSWER 4 OF 84 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:699768 CAPLUS
DOCUMENT NUMBER: 145:145462
TITLE: Preparation of haloaryl substituted aminopurines for use as a prodrug in the treatment of cancers , cardiovascular or renal diseases
INVENTOR(S): Albers, Ronald; Ayala, Leticia; Clareen, Steven S.; Delgado Mederos, Maria M.; Hilgraf, Robert; Hedge, Sayee; Hughes, Kevin; Kois, Adam; Plantevin-Krenitsky, Veronique; McCarrick, Meg; Nadolny, Lisa; Palanki, Moorthy; Sahasrabudhe, Kiran; Sapienza, John; Satoh, Yoshitaka; Sloss, Marian; Sudbeck, Elise; Wright, Jonathan
PATENT ASSIGNEE(S): Signal Pharmaceuticals, LLC, USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006076595	A1	20060720	WO 2006-US1275		20060113
WO 2006076595	A8	20061005			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 2006287344	A1	20061221	US 2006-332617		20060112
PRIORITY APPLN. INFO.:			US 2005-643796P	P	20050113
			US 2005-709980P	P	20050819

OTHER SOURCE(S): MARPAT 145:145462
GI



I



II

AB Haloaryl substituted aminopurines I, wherein R1 is an (un)substituted C1-6alkyl, (un)substituted aryl, (un)substituted C3-10cycloalkyl, (un)substituted C3-10heterocycle or (un)substituted C3-10heteroaryl groups; R2 is H, (un)substituted C1-6alkyl, unsubstituted aryl, (un)substituted C3-10cycloalkyl, (un)substituted C3-10heterocycle or (un)substituted C3-10heteroaryl; and R3 is is an aryl substituted with one or more halogens, C3-10heteroaryl substituted with one or more halogens, wherein the aryl or C3-10heteroaryl group is substituted with one or more C1- 6alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, aminocarbonyl, cyano, acylamino, alkanesulfonylamino, tetrazolyl, triazolyl or imidazolyl groups are prepared Thus, II was prepared and tested as an anticancer agent in an Alamar Blue Assay for chronic myelogenous leukemia K562 cells (no data). Further, I, when tested in the same anticancer assay have displayed IC50 values ranging from 0.1 to 10 μM. Addnl., I can be used in the treatment of cardiovascular diseases, renal diseases, autoimmune conditions, as an antiinflammatory, macular degeneration, ischemia-reperfusion injury, pain, disease-related wasting, asbestos-related conditions, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway.

IT 899801-05-9P 899801-06-0P 899801-66-2P
899801-69-5P 899801-70-8P 899801-73-1P
899801-87-7P 899801-94-6P 899801-97-9P
899801-98-0P 899801-99-1P 899802-07-4P
899802-08-5P 899802-12-1P 899802-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of haloaryl substituted aminopurines for use as a prodrug in the treatment of cancers, cardiovascular or renal diseases)

RN 899801-05-9 CAPLUS

CN Acetamide, N-[trans-4-[8-[(2-fluorophenyl)amino]-2-[(4-methoxyphenyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-06-0 CAPLUS

CN Acetamide, N-[trans-4-[[9-cyclopentyl-8-[(2-fluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-66-2 CAPLUS
CN Acetamide, N-[trans-4-[2-[(trans-4-aminocyclohexyl)amino]-8-[(2-fluorophenyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-69-5 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[(4-methoxyphenyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-70-8 CAPLUS
CN Acetamide, N-[cis-4-[8-[(2-fluorophenyl)amino]-2-[(4-methoxyphenyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-73-1 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2-fluorophenyl)amino]-2-[(1-methylethyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-87-7 CAPLUS
CN Acetamide, N-[cis-4-[[9-cyclopentyl-8-[(2-fluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-94-6 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[(4-fluorophenyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-97-9 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2-fluorophenyl)amino]-2-[(trans-4-hydroxycyclohexyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-98-0 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[(trans-4-hydroxycyclohexyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899801-99-1 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[(1-methylethyl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899802-07-4 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2-fluorophenyl)amino]-2-[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899802-08-5 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[(tetrahydro-2H-pyran-4-yl)amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899802-12-1 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2-fluorophenyl)amino]-2-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 899802-13-2 CAPLUS
CN Acetamide, N-[trans-4-[8-[(2,4-difluorophenyl)amino]-2-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]amino]-9H-purin-9-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 84 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:1252836 CAPLUS
TITLE: Thiazole derivatives and their preparation, pharmaceutical compositions, and use for treatment of various diseases
INVENTOR(S): Quattropani, Anna; Covini, David; Pomel, Vincent; Dorbais, Jerome; Rueckle, Thomas
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N. V., Neth. Antilles
SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125807	A1	20061130	WO 2006-EP62602	20060524

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-104418 A 20050524
US 2005-686266P P 20050601

GI



AB The invention is related to thiazole derivs. of formula I in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. Compds. of formula I wherein R1 is (hetero)aryl, (hetero)cycloalkyl and acyl; R2 is H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; R3 is (un)substituted thienyl; and their geometrical isomers, optically active enantiomers, diastereoisomers, racemates, and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by cross-coupling of N-(5-iodo-4-methyl-1,3-thiazol-2-yl)acetamie with 5-formyl-2-

thiopheneboronic acid. All the invention compds. were evaluated for their PI2Kγ inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 0.215 μM.

IT 916137-93-4P 916137-96-7P 916137-98-9P
916138-06-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of thiazole derivs. useful in treatment and prophylaxis of diseases)

RN 916137-93-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916137-96-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916137-98-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-06-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 916137-94-5P 916137-95-6P 916137-97-8P
916137-99-0P 916138-00-6P 916138-01-7P
916138-02-8P 916138-03-9P 916138-04-0P
916138-05-1P 916138-07-3P 916138-08-4P
916138-09-5P 916138-10-8P 916138-11-9P
916138-12-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazole derivs. useful in treatment and prophylaxis of diseases)

RN 916137-94-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916137-95-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916137-97-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916137-99-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-00-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-01-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-02-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-03-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-04-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-05-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-07-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-08-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-09-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-10-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-11-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 916138-12-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



IT 916138-14-2P 916138-15-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazole derivs. useful in treatment and prophylaxis of diseases)
RN 916138-14-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 916138-15-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
     (FILE 'HOME' ENTERED AT 14:33:47 ON 22 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 14:34:08 ON 22 DEC 2006

     FILE 'CAPLUS' ENTERED AT 14:34:16 ON 22 DEC 2006
L1             2 S 311773-65-6/RN
                 SELECT L1 1 RN
L2         16462 S E1-E5
L3          8081 S L2 AND (CANCER OR TUMOR OR CANCER? OR NEOPLASTIC OR NEOPLAS?
L4          3751 S L3 AND (OVARIAN OR OVARY OR PERITONEAL OR ENDOMETRIAL OR CERV
L5           137 S L4 AND (OV202 OR HTC OR CAOV OR MDA-MD OR HUVEC OR A431 OR HT
L6           137 FOCUS L5 1-

     FILE 'REGISTRY' ENTERED AT 14:38:00 ON 22 DEC 2006
L7             1 S 127464-60-2/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY
L8             0 S L4 NOT 127464-60-2/RN
L9             0 S L4 NOT 127464-60-2/RN
L10            4 S L2 NOT 127464-60-2/RN

     FILE 'CAPLUS' ENTERED AT 14:40:54 ON 22 DEC 2006
L11            5 S L10

     FILE 'REGISTRY' ENTERED AT 14:45:11 ON 22 DEC 2006
L12              STRUCTURE UPLOADED
L13              STRUCTURE UPLOADED
L14            5 S SSS FULL L13
L15        22549 S SSS L12 FULL

     FILE 'CAPLUS, USPATFULL' ENTERED AT 14:52:40 ON 22 DEC 2006
L16            3 S L14
L17         2326 S L15
L18            2 DUP REM L16 (1 DUPLICATE REMOVED)
L19          453 S L17 AND (CANCER OR TUMOR OR CANCER? OR NEOPLASTIC OR NEOPLAS?
L20          252 S L19 AND (OVARIAN OR OVARY OR PERITONEAL OR ENDOMETRIAL OR CER
L21          236 DUP REM L20 (16 DUPLICATES REMOVED)
L22          315 S L17 AND (CARDIOVASCULAR OR ATHEROSCLEROSIS OR ARTERIOSCLEROSI
L23          189 S L22 AND (CANCER OR TUMOR OR CANCER? OR NEOPLASTIC OR NEOPLAS?
L24          178 DUP REM L23 (11 DUPLICATES REMOVED)
L25           84 S L24 AND ATHEROSCLEROSIS
L26           84 FOCUS L25 1-

=> s l26 and pd<= 2003
L27            0 L26 AND PD<= 2003

=> s l26 and pd <= 2003
L28            0 L26 AND PD <= 2003

=> s l24 and pd <= 2003
L29            0 L24 AND PD <= 2003

=>
```

L38 ANSWER 43 OF 60 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:741728 CAPLUS
DOCUMENT NUMBER: 139:290273
TITLE: High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells
AUTHOR(S): Nofer, Jerzy-Roch; Geigenmuller, Sven; Gopfert, Christian; Assmann, Gerd; Buddecke, Eckhart; Schmidt, Annette
CORPORATE SOURCE: Institut fur Klinische Chemie und Laboratoriumsmedizin, Westfalische Wilhelms-Universitat, Munster, Germany
SOURCE: Biochemical and Biophysical Research Communications (2003), 310(1), 98-103
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Adhesion and recruitment of blood monocytes, processes mediated by cell adhesion mols. including E-selectin, represent an early event in atherogenesis. High d. lipoproteins (HDLs) were shown to inhibit cytokine-induced expression of adhesion mols., but mechanisms underlying this effect are not fully understood. We here investigated the effects of sphingosylphosphorylcholine (SPC) and lysosulfatide (LSF), two lysosphingolipids associated with HDL, on TNF-α-induced E-selectin expression in human umbilical endothelial cells. We found that HDL, SPC, and LSF inhibited E-selectin expression both on mRNA and protein level. In addition, all three agents reduced the number of E-selectin mols. present on endothelial cell surface. The inhibitory effects of HDL, SPC, and LSF on TNF-α-induced E-selectin expression were partially reverted in the presence of suramin, an antagonist of lysosphingolipid receptor EDG-3, or pertussis toxin, an inhibitor of trimeric G proteins. In addition, inhibition of activation of protein kinase Akt with LY294002 but not inhibition of phosphatidylinositol-specific phospholipase C (PI-PLC) with U73122 abolished the restrictive effects of HDL-, SPC-, or LSF on E-selectin expression. We conclude that HDL-associated lysosphingolipids may at least partially account for the inhibitory effects of HDL on cytokine-induced expression of adhesion mols., and that activations of G-protein-coupled receptors and protein kinase Akt are involved in this process.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 44 OF 60 USPATFULL on STN

L38 ANSWER 44 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2002:213774 USPATFULL
TITLE: 14275 receptor, a novel G-protein coupled receptor related to the EDGreceptor family
INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Hodge, Martin R., Arlington, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002115150	A1	20020822	<--
APPLICATION INFO.:	US 2001-7399	A1	20011105 (10)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-390039, filed on 3 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-146416, filed on 3 Sep 1998, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 4004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a newly identified member of the superfamily of G-protein-coupled receptors, and a new member of the EDG receptor family. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 47 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2002:235439 USPATFULL
TITLE: Enzyme method for detecting sphingosine-1-phosphate (S1P)
INVENTOR(S): Skinner, Michael K., Pullman, WA, UNITED STATES
Johnson, Jodi L., Beaverton, OR, UNITED STATES
Parrott, Jeff A., Irvine, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002127628	A1	20020912	<--
	US 6716595	B2	20040406	
APPLICATION INFO.:	US 2002-133012	A1	20020426 (10)	

RELATED APPLN. INFO.: Division of Ser. No. US 2000-661988, filed on 14 Sep 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 748
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.

L38 ANSWER 53 OF 60 USPATFULL on STN

ACCESSION NUMBER:	2002:258805 USPATFULL
TITLE:	Mammalian EDG-7 receptor homologs
INVENTOR(S):	Munroe, Donald G., Waterdown, CANADA Gupta, Ashwani K., Mississauga, CANADA Zastawny, Roman L., Etobicoke, CANADA
PATENT ASSIGNEE(S):	Allelix Pharmaceuticals, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142375	A1	20021003	<--
	US 6566096	B2	20030520	
APPLICATION INFO.:	US 2000-731030	A1	20001207 (9)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-221851, filed on 29 Dec 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-70184P	19971230 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ARENT FOX KINTNER PLOTKIN & KAHN, PLLC, Suite 600, 1050 Connecticut Avenue, N.W., Washington, DC, 20036-5339
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	17 Drawing Page(s)
LINE COUNT:	2452

AB The present invention is directed to nucleic acid sequence and amino acid sequences for mammalian EDG-7 receptor homologs, and particularly for human EDG-7 receptor homologs. The invention also provides methods for determining agonists and antagonsits for EDG-7 receptors in addition to assays, expression vectors, host cells and methods for treating disorders associated with abherrent expression or activity of EDG-7.

L38 ANSWER 54 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2002:24362 USPATFULL
TITLE: Human EDG3sb gene
INVENTOR(S): Tsui, Ping, Berwyn, PA, United States
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6344542	B1	20020205	<--
APPLICATION INFO.:	US 2000-546117		20000410 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1998-82088, filed on 20 May 1998, now patented, Pat. No. US 6130067
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Han, William T., Ratner & Prestia, King, William T.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The EDG3sb polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EDG3sb polypeptides and polynucleotides in therapy, and diagnostic assays for

38 ANSWER 59 OF 60 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:590932 CAPLUS
DOCUMENT NUMBER: 139:149413
TITLE: Selective S1P1/Edg1 receptor agonists
INVENTOR(S): Doherty, George A.; Forrest, Michael J.; Hajdu, Richard; Hale, Jeffrey J.; Li, Zhen; Mandala, Suzanne M.; Mills, Sander G.; Rosen, Hugh; Scolnick, Edward M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061567	A2	20030731	WO 2003-US1120	20030114 <--
WO 2003061567	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004058894	A1	20040325	US 2003-339380	20030109
CA 2472680	A1	20030731	CA 2003-2472680	20030114 <--
EP 1469863	A2	20041027	EP 2003-731917	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005070506	A1	20050331	US 2004-501176	20040712

PRIORITY APPLN. INFO.:		
US 2002-349991P	P	20020118
US 2002-362566P	P	20020307
US 2002-382933P	P	20020523
WO 2003-US1120	W	20030114

AB The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Thus, 4-HOC6H4CHO was treated with Me(CH2)7I to give 4-Me(CH2)7OC6H4CHO which was treated with H2N(CH2)3P(O)(OH)2 to give 4-Me(CH2)7OC6H4CH2NH(CH2)3P(O)(OH)2 which had an EC50 for S1P1 agonism of 1.5 nM and for S1P3 agonism of 6.0 nM.

L38 ANSWER 6 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2003:38153 USPATFULL
TITLE: LPA receptor agonists and antagonists and methods of use
INVENTOR(S): Miller, Duane D., Germantown, TN, UNITED STATES
Tigyi, Gabor, Memphis, TN, UNITED STATES
Dalton, James T., Columbus, OH, UNITED STATES
Sardar, Vineet M., Cordova, TN, UNITED STATES
Elrod, Don B., College Station, TX, UNITED STATES
Xu, Huiping, Columbus, OH, UNITED STATES
Baker, Daniel L., Memphis, TN, UNITED STATES
Wang, Dean, Memphis, TN, UNITED STATES
Liliom, Karoly, Budapest, HUNGARY
Fischer, David J., Plymouth, MA, UNITED STATES
Virag, Tamas, Memphis, TN, UNITED STATES
Nusser, Nora, Memphis, TN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003027800	A1	20030206	<--
	US 6875757	B2	20050405	
APPLICATION INFO.:	US 2001-811838	A1	20010319	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190370P	20000317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael L. Goldman, NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 4588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 6 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2003:38153 USPATFULL
TITLE: LPA receptor agonists and antagonists and methods of use
INVENTOR(S): Miller, Duane D., Germantown, TN, UNITED STATES
Tigyi, Gabor, Memphis, TN, UNITED STATES
Dalton, James T., Columbus, OH, UNITED STATES
Sardar, Vineet M., Cordova, TN, UNITED STATES
Elrod, Don B., College Station, TX, UNITED STATES
Xu, Huiping, Columbus, OH, UNITED STATES
Baker, Daniel L., Memphis, TN, UNITED STATES
Wang, Dean, Memphis, TN, UNITED STATES
Liliom, Karoly, Budapest, HUNGARY
Fischer, David J., Plymouth, MA, UNITED STATES
Virag, Tamas, Memphis, TN, UNITED STATES
Nusser, Nora, Memphis, TN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003027800	A1	20030206	<--
	US 6875757	B2	20050405	
APPLICATION INFO.:	US 2001-811838	A1	20010319	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190370P	20000317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael L. Goldman, NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 4588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 7 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2003:312185 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Research Institute at Oakland, Oakland, CA, UNITED STATES, 94609-1673 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219782	A1	20031127	<--
APPLICATION INFO.:	US 2003-348052	A1	20030117	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 8 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2003:188444 USPATFULL
TITLE: LPA receptor agonists and antagonists and methods of use
INVENTOR(S): Miller, Duane D., Germantown, TN, UNITED STATES
Tigyi, Gabor, Memphis, TN, UNITED STATES
Dalton, James T., Columbus, OH, UNITED STATES
Sardar, Vineet M., Cordova, TN, UNITED STATES
Elrod, Don B., College Station, TX, UNITED STATES
Xu, Huiping, Memphis, TN, UNITED STATES
Baker, Daniel L., Memphis, TN, UNITED STATES
Wang, Dean, Memphis, TN, UNITED STATES
Liliom, Karoly, Budapest, HUNGARY
Fischer, David J., Cordova, TN, UNITED STATES
Virag, Tamas, Memphis, TN, UNITED STATES
Nusser, Nora, Memphis, TN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130237	A1	20030710	<--
APPLICATION INFO.:	US 2001-953686	A1	20010918 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-811838, filed on 19 Mar 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190370P	20000317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael L. Goldman, NIXON PEABODY LLP, Clinton Square, P.O. Box 31051, Rochester, NY, 14603
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 4417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating

cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 9 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2002:259409 USPATFULL
TITLE: Method for regulating angiogenesis
INVENTOR(S): Hla, Timothy, Avon, CT, UNITED STATES
Lee, Meng-Jer, Unionville, CT, UNITED STATES
Claffey, Kevin P., Burlington, CT, UNITED STATES
Ancellin, Nicolas, Farmington, CT, UNITED STATES
Thangada, Shobha, Glastonbury, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142982	A1	20021003	<--
APPLICATION INFO.:	US 2001-945353	A1	20010831 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-651846, filed on 31 Aug 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152266P	19990902 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CANTOR COLBURN, LLP, 55 GRIFFIN ROAD SOUTH, BLOOMFIELD, CT, 06002
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 1830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the inhibition of angiogenesis are presented, comprising affecting the response of the EDG-1 receptor by the administration of pharmaceutically effective antagonists of EDG-1 signal transduction. This invention is based in part on the discovery that Akt protein kinase phosphorylation is required for endothelial cell chemotaxis mediated by the EDG-1 G protein-coupled receptor. This invention relates to the use of modifiers of EDG-1 signal transduction to treat disorders of undesired angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 10 OF 60 USPATFULL on STN
ACCESSION NUMBER: 2003:306406 USPATFULL
TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules
INVENTOR(S): Logan, Thomas J., Springfield, PA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Healy, Aileen, Medford, MA, UNITED STATES
Acton, Susan L., Lexington, MA, UNITED STATES
Donoghue, Mary A., West Roxbury, MA, UNITED STATES

Stagliano, Nancy, North Reading, MA, UNITED STATES
Perodin, Jacqueline, Arlington, MA, UNITED STATES
Rodrigue-Way, Amelie, Malden, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003215840	A1	20031120	<--
APPLICATION INFO.:	US 2003-353690	A1	20030129	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353224P	20020201 (60)
	US 2002-364529P	20020315 (60)
	US 2002-373861P	20020419 (60)
	US 2002-376287P	20020429 (60)
	US 2002-388080P	20020612 (60)
	US 2002-390971P	20020624 (60)
	US 2002-394130P	20020703 (60)
	US 2002-394797P	20020710 (60)
	US 2002-404904P	20020821 (60)
	US 2002-405450P	20020823 (60)
	US 2002-408070P	20020904 (60)
	US 2002-424300P	20021106 (60)
	US 2002-431079P	20021205 (60)
	US 2002-431042P	20021205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 15913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.